Insider Selling: Fractyl Health, Inc. (NASDAQ:GUTS) Insider Sells 64,197 Shares of Stock

Fractyl Health, Inc. (NASDAQ:GUTS) insider Jay David Caplan sold 64,197 shares of the business’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $2.47, for a total transaction of $158,566.59. Following the completion of the transaction, the insider now owns 153,544 shares in the company, valued at $379,253.68. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Jay David Caplan also recently made the following trade(s):

• On Thursday, September 12th, Jay David Caplan sold 65,000 shares of Fractyl Health stock. The stock was sold at an average price of $2.90, for a total value of $188,500.00.

Fractyl Health Price Performance

NASDAQ:GUTS traded down $0.06 during mid-day trading on Wednesday, reaching $2.37. 375,016 shares of the stock were exchanged, compared to its average volume of 318,194. Fractyl Health, Inc. has a 1-year low of $1.74 and a 1-year high of $14.50. The company has a current ratio of 7.46, a quick ratio of 7.46 and a debt-to-equity ratio of 0.40. The firm has a market capitalization of $113.59 million and a PE ratio of -0.19. The business has a fifty day moving average price of $2.63 and a 200 day moving average price of $4.05.

Fractyl Health (NASDAQ:GUTS) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.48) earnings per share for the quarter, topping the consensus estimate of ($0.50) by $0.02. The firm had revenue of $0.01 million for the quarter. Research analysts expect that Fractyl Health, Inc. will post -1.61 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Fractyl Health

Several hedge funds have recently modified their holdings of GUTS. Rhumbline Advisers bought a new position in shares of Fractyl Health during the second quarter worth approximately $32,000. SG Americas Securities LLC purchased a new stake in shares of Fractyl Health in the third quarter worth approximately $33,000. Beta Wealth Group Inc. purchased a new position in shares of Fractyl Health in the 3rd quarter worth about $44,000. BNP Paribas Financial Markets increased its stake in shares of Fractyl Health by 54.1% in the third quarter. BNP Paribas Financial Markets now owns 21,072 shares of the company’s stock worth $53,000 after purchasing an additional 7,397 shares in the last quarter. Finally, Renaissance Technologies LLC bought a new stake in Fractyl Health during the second quarter valued at $61,000.

About Fractyl Health

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.